Use of cotinine in treating or preventing neurogenesis deficits and enhancing neurogenesis
AssigneesThe United States of America as represented by the Department of Veterans Affairs, University of South Florida
InventorsValentina Echeverria Moran, Doreen Appunn
Life of this patent
Estimating the term…
Abstract
A method of inhibiting or treating chemotherapy-induced cognitive dysfunction comprising administering a therapeutically effective amount of cotinine to a cancer patient experiencing chemotherapy-induced cognitive dysfunction.
Claims18
A method of reducing chemotherapy-induced cognitive dysfunction comprising administering a therapeutically effective amount of cotinine to a cancer patient experiencing chemotherapy-induced cognitive dysfunction, wherein the therapeutically effective amount of cotinine is about 0.1 mg/kg to about 10 mg/kg.
A method of reducing chemotherapy-induced memory loss or depression comprising administering a therapeutically effective amount of cotinine to a cancer patient experiencing chemotherapy-induced memory loss or depression, wherein the therapeutically effective amount of cotinine is about 0.1 mg/kg to about 10 mg/kg.
A method of reducing chemotherapy-induced memory loss or depression comprising administering a therapeutically effective amount of cotinine to a cancer patient prior to chemotherapy or prior to onset of chemotherapy-induced memory loss or depression, wherein the therapeutically effective amount of cotinine is about 0.1 mg/kg to about 10 mg/kg.
Dependencies are inferred from the claim text.